News Headlines Article

As new Gilead CEO enters, cancer chief exits
San Francisco Business Times

Little more than two years after joining Gilead Sciences Inc. to lead the company’s cancer fight, Dr. Alessandro Riva is leaving for an East Coast spinoff of an Indian drug maker.

The move comes just days after Daniel O’Day took over the Foster City-based company (NASDAQ: GILD) as chairman and CEO. It continues a wave of Gilead departures.

Riva, who will continue as Gilead’s executive vice president of oncology therapeutics and cell therapy through the end of the month, will become CEO of a 400-person spinoff of India’s Glenmark Pharmaceuticals. He will start the new job, based in Paramus, N.J., on April 2.